Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Valneva Confirms Step Back From COVID-19 Vaccine Development
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.

Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India

2seventy/BMS’s Abecma Shines In Earlier Lines, But J&J/Legend’s Carvykti May Have Edge
Without disclosing data, 2seventy and BMS reported positive Phase III results in third-line and beyond multiple myeloma, but Carvykti will soon have second-line data.

Verona Transformed After Phase III Victory For COPD Therapy
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.

Strides’ Stelis Moves Closer To EU Nod For Forteo Biosimilar In FY23
Strides’ biopharma arm Stelis Biopharma has moved closer to approval in the EU and likely the US too for a biosimilar to Eli Lilly’s Forteo in FY23, following GMP certification for its manufacturing units. Meanwhile, merchant bankers have been appointed to evaluate strategic options to raise cash for Stelis.

Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Galapagos Keeps Analysts Guessing About Future Plans
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.

Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge
Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.